<DOC>
	<DOCNO>NCT01677676</DOCNO>
	<brief_summary>This study design evaluate safety immunogenicity two different formulation FP-01.1 well build data set first human study FP-01.1_CS_01 . It anticipate result Phase I study inform best formulation vaccine evaluate efficacy study .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Two Different Formulations Influenza A Vaccine ( FP-01.1 )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Age 18 55 year inclusive time consent 2 . Willing comply applicable contraceptive requirement protocol • For male subject , agreement use barrier method ( condom ) method birth control addition contraceptive measure normally take partner completion Day 57 visit , refrain father child least completion ofthe Day 57 visit . Male subject need use contraception partner menopause , womb ovary remove . OR • For female subject childbearing potential , surgically sterile use insertable , injectable , transdermal , combination oral contraceptive approve TGA combine barrier contraceptive completion Day 57 visit study negative result serum urine pregnancy test do administration study medication ( woman postmenopausal [ menses least 2 year ] also eligible participate ) 3 . Satisfactory medical assessment clinically significant relevant abnormality medical history , physical examination , vital sign , ECG laboratory evaluation ( haematology , biochemistry urinalysis ) assess Investigator . 4 . An understanding , ability willingness fully comply study procedure restriction 5 . Ability provide write , personally sign date informed consent participate study . 6 . The subject body mass index ( BMI ) within range 19.032.0 kg/m2 fall within weight range 50.0100.0 kg . 7 . The subject willing present study prepare letter General Practitioner ( GP ) visit purpose 8 . Subject willing refrain consume alcohol 24h prior visit . 1 . As result medical screening process , Principal Investigator CoInvestigator considers subject unfit study . 2 . Current , chronic recurrent disease ( e.g . cardiovascular , respiratory , endocrine , renal , liver , gastrointestinal , autoimmune , immune suppression , malignancy condition ) could affect action , absorption disposition IMP could affect clinical laboratory assessment . 3 . Significant illness judge Principal Investigator CoInvestigator within 2 week first dose IMP . 4 . Subjects history allergy allergic condition include anaphylactic reaction , asthmatic , hay fever eczema sufferer require medication opinion Principal Investigator CoInvestigator affect participation study . 5 . Subjects receive medication affect immune system include systemic steroid patient chronic medication dose stable least 3 month . 6 . Known suspected intolerance hypersensitivity IMP , closely related compound state ingredient 7 . History alcohol substance abuse within last year . A positive screen alcohol drug abuse . 8 . Male subject consume 21 unit alcohol per week female subject consume 14 unit alcohol per week . 9 . A positive HIV antibody screen , Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody screen 10 . Subjects significant scarring , tattoo , abrasion , cut infection , opinion Investigator could interfere evaluation injection site local reaction , deltoid region arm dose site . 11 . Donation blood blood product ( e.g . plasma , platelet ) within 90 day prior intention donate blood entire study . 12 . Use another investigational medicinal product within 90 day prior receive first dose IMP intention enrol another clinical study throughout entire study ( include Day 57 ) , include 6 month followup period subject consent remain study followup . 13 . Subject suspect recent ( ≤12 month ) preexposure influenza A virus flu like symptom associate ≥ 2 day normal daily activity 14 . Subjects receive flu vaccine last 12 month anticipate receive within duration clinical phase study ( ie completion Day 57 ) period 6 month safety followup telephone call , subject consent remain study followup . 15 . Any clinically significant abnormality , opinion Principal Investigator CoInvestigator , electrocardiogram ( ECGs ) , assess clinical site 's reference range . In addition , subject , complete medical history questionnaire take part consent study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Influenza A</keyword>
</DOC>